Aussie Prana’s Alzheimer’s Drug Shows Promising Early Data
This article was originally published in PharmAsia News
Executive Summary
A drug developed by Prana Biotechnology of Australia has demonstrated in an early trial a possible cure for Alzheimer's disease. The drug PBT2 works by preventing the abeta protein from combining with metals in the brain, a combination believed to cause toxic effects on the brain. The Prana-supported research was published in The Lancet medical journal. Prana is an academic spinoff of the University of Melbourne. The company's CEO, Geoffrey Kempler, said the drug could be the world's first treatment of the underlying causes of Alzheimer's. (Click here for more